Research progress of immunotherapies on correction of immunoparalysis in sepsis
10.12206/j.issn.2097-2024.202203113
- VernacularTitle:免疫治疗纠正脓毒症免疫麻痹的研究进展
- Author:
Xinhao XING
1
;
Linlin CHEN
1
;
Zhongyi LING
2
;
Yan WANG
1
Author Information
1. Center for Drug Discovery and Development, School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
- Keywords:
immunotherapy;
sepsis;
immunoparalysis;
cytokines;
immune checkpoint;
immunoreactive substances
- From:
Journal of Pharmaceutical Practice
2023;41(1):1-7
- CountryChina
- Language:Chinese
-
Abstract:
Immunoparalysis is the main cause of death in patients with intermediate and terminal sepsis. The correction of immunoparalysis is an important direction of sepsis treatment. In the pathological process of sepsis, a variety of factors contribute to the imbalanced secretion of cytokines, weakened function of antigen-presenting cells, apoptosis and depletion of lymphocytes, and ultimately lead to immunoparalysis, secondary infection, and even patient deaths. Cytokines such as GM-CSF, IFN-γ, IL-7, and IL-15, immune checkpoint-related therapies such as PD-1/PD-L1 antibodies, CTLA-4 antibodies, TIM-3 antibodies, and LAG-3 antibodies, and immunoreactive substances such as thymosin α1 and immunoglobulin might be beneficial to correct the immune paralysis of patients. the progress of immunotherapy to correct immune paralysis in sepsis were reviewed in this article.
